MedTrace Logo

Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis

NCT00638456 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-08-14

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate whether or not oral viscous budesonide is effective in treating children with Eosinophilic Esophagitis.

Conditions

  • Eosinophilic Esophagitis

Interventions

DRUG

Budesonide plus Prevacid

Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.

DRUG

placebo plus Prevacid

Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.

Sponsors & Collaborators

  • Meritage Pharma, Inc.

    collaborator INDUSTRY

  • Ranjan Dohil

    lead OTHER

Principal Investigators

  • Ranjan Dohil, MD · UCSD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00638456 on ClinicalTrials.gov